Cardio-oncology & other

Nirmatrelvir-Ritonavir for Acute COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection

JACC AdvPublished Retrospective cohort study

Authors' conclusion

NMV-r in nonhospitalized vaccinated patients with pre-existing CVD with COVID-19 was associated with a reduction in PASC and health care utilization.

Study context

Population
Nonhospitalized, vaccinated patients with pre-existing cardiovascular disease (CVD) who developed COVID-19, December 2021 to December 2022matched cohorts
Participants
26,953 vs 26,953
Exposure
Nirmatrelvir-ritonavir (NMV-r) vs no NMV-r within 5 days of COVID-19 diagnosis
  • NMV-rn = 26,953
  • non-NMV-rn = 26,953reference
Outcome
Presence of PASC
Follow-up
30 to 90 days and 90 to 180 days after index COVID-19 infection
Methodological detailspropensity-score matched, TriNetX research network
  • Propensity-score matched
  • TriNetX research network

Main finding

As reported in the abstract

PASC

NMV-r

Broad PASC, 30–90 days
6,925 (26%)
Broad PASC, 90–180 days
6,692 (25.1%)
Narrow PASC, 30–90 days
5,335 (20%)
Narrow PASC, 90–180 days
5,121 (19.2%)

non-NMV-r

Broad PASC, 30–90 days
8,150 (30.6%)
Broad PASC, 90–180 days
8,910 (33.5%)
Narrow PASC, 30–90 days
6,271 (23.6%)
Narrow PASC, 90–180 days
6,964 (26.1%)

Broad PASC, 30–90 days

NMV-r6,925 (26%)
non-NMV-r8,150 (30.6%)

Broad PASC, 90–180 days

NMV-r6,692 (25.1%)
non-NMV-r8,910 (33.5%)

Narrow PASC, 30–90 days

NMV-r5,335 (20%)
non-NMV-r6,271 (23.6%)

Narrow PASC, 90–180 days

NMV-r5,121 (19.2%)
non-NMV-r6,964 (26.1%)
NMV-r vs non-NMV-rOdds ratio (95% CI)P value
Broad PASC, 30–90 days
0.80(0.76–0.82)
P < 0.001
Broad PASC, 90–180 days
0.25(0.23–0.29)
P < 0.001
Narrow PASC, 30–90 days
0.81(0.78–0.84)
P < 0.001
Narrow PASC, 90–180 days
0.67(0.64–0.70)
P < 0.001

Observational data: associations, not effects.

Original publication

Nirmatrelvir-Ritonavir for Acute COVID-19 in Patients With Cardiovascular Disease and Postacute Sequelae of SARS-CoV-2 Infection. JACC Adv. Published 26 June 2024. doi:10.1016/j.jacadv.2024.100961

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.